MiMedx Group, Inc. (MDXG)
4.28
-0.05
(-1.15%)
USD |
NASDAQ |
Aug 24, 16:00
4.28
0.00 (0.00%)
After-Hours: 20:00
MiMedx Group Enterprise Value : 512.35M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 512.35M |
| August 20, 2026 | 507.98M |
| August 19, 2026 | 529.84M |
| August 18, 2026 | 513.81M |
| August 17, 2026 | 491.95M |
| August 14, 2026 | 503.61M |
| August 13, 2026 | 493.41M |
| August 12, 2026 | 505.07M |
| August 11, 2026 | 510.90M |
| August 10, 2026 | 503.61M |
| August 07, 2026 | 513.81M |
| August 06, 2026 | 490.50M |
| August 05, 2026 | 487.58M |
| August 04, 2026 | 503.61M |
| August 03, 2026 | 503.61M |
| July 31, 2026 | 483.21M |
| July 30, 2026 | 503.61M |
| July 29, 2026 | 497.78M |
| July 28, 2026 | 516.73M |
| July 27, 2026 | 502.15M |
| July 24, 2026 | 493.41M |
| July 23, 2026 | 483.21M |
| July 22, 2026 | 489.04M |
| July 21, 2026 | 510.90M |
| July 20, 2026 | 512.35M |
| Date | Value |
|---|---|
| July 17, 2026 | 507.98M |
| July 16, 2026 | 526.93M |
| July 15, 2026 | 503.61M |
| July 14, 2026 | 493.41M |
| July 13, 2026 | 475.92M |
| July 10, 2026 | 480.29M |
| July 09, 2026 | 484.67M |
| July 08, 2026 | 502.15M |
| July 07, 2026 | 493.41M |
| July 06, 2026 | 474.47M |
| July 02, 2026 | 456.98M |
| July 01, 2026 | 449.69M |
| June 30, 2026 | 442.41M |
| June 29, 2026 | 440.14M |
| June 26, 2026 | 443.12M |
| June 25, 2026 | 425.25M |
| June 24, 2026 | 428.23M |
| June 23, 2026 | 413.34M |
| June 22, 2026 | 404.40M |
| June 18, 2026 | 404.40M |
| June 17, 2026 | 395.46M |
| June 16, 2026 | 408.87M |
| June 15, 2026 | 405.89M |
| June 12, 2026 | 393.97M |
| June 11, 2026 | 407.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 278.32M |
| Perspective Therapeutics, Inc. | 143.57M |
| ABVC BioPharma, Inc. | 28.48M |
| Enovis Corp. | 2.861B |
| Edwards Lifesciences Corp. | 48.33B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.84M |
| Revenue (Quarterly) | 64.36M |
| Total Expenses (Quarterly) | 79.20M |
| EPS Diluted (Quarterly) | -0.1004 |
| Gross Profit Margin (Quarterly) | 68.50% |
| Profit Margin (Quarterly) | -23.06% |
| Earnings Yield | 0.92% |
| Operating Earnings Yield | 1.37% |
| Normalized Earnings Yield | 0.9205 |